STOCKHOLM (Reuters) -Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial
Novo Nordisk Seeks Approval for Higher Dose of Wegovy in Europe
STOCKHOLM (Reuters) -Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.
Novo Nordisk said in a statement it aimed to make the higher dose available throughout the European Union.
"This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity," it said.
(Reporting by Anna Ringstrom. Editing by Essi Lehto and Mark Potter)
